GlassScriptPhysician profile
Rani Lall
NPI 1598021180
$2,001.66
in general payments reported to CMS, 2019-2025
19 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $121 · 2021: $151 · 2022: $417 · 2023: $372 · 2024: $347 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $233.09 | 2022-2025 | Nexletol |
| Amgen INC. | $215.54 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $212.65 | 2020-2024 | |
| Boston Scientific Corporation | $195.61 | 2019 | |
| Pfizer INC. | $152.06 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.73 | 2021-2023 | Jardiance |
| Heartflow, INC. | $142.33 | 2022-2025 | |
| Edwards Lifesciences Corporation | $138.82 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Janssen Pharmaceuticals, INC | $131.04 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.20 | 2020-2021 | |
| Inspire Medical Systems, INC. | $81.02 | 2024-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $75.42 | 2020-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $58.96 | 2022-2023 | Verquvo |
| Lantheus Medical Imaging, INC. | $23.78 | 2023 | Definity |
| Amarin Pharma, INC. | $19.66 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $16.38 | 2023 | Movantik |
| Astrazeneca Pharmaceuticals LP | $16.02 | 2023 | Wainua |
| Chiesi USA, INC. | $15.10 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Lall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.